LMNTS news

Latest 2 stories · newest Jun 3, 2026

LMNTS

Liminatus Pharma issues common stock purchase warrants under Securities Act exemption

Liminatus Pharma filed a warrant agreement allowing holders to purchase common stock at a specified exercise price through 2031. The unregistered securities offering provides capital formation flexibility for the pharmaceutical company.

Offering Jun 3, 2026 sentiment +0.50 SEC filing ↗

LMNTS

Liminatus Pharma to acquire InnocsAI LLC in merger agreement dated May 17, 2026

Liminatus Pharma, Inc. has entered into a merger agreement to acquire InnocsAI LLC, a Delaware limited liability company. The transaction represents a significant corporate combination for the pharmaceutical company.

M&A May 20, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same LMNTS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/LMNTS/newsSTART FREE